New research suggests alternative treatment target for schizophrenia

February 3, 2016 by Anne Dreyfuss And Rachel Machacek
Functional magnetic resonance imaging (fMRI) and other brain imaging technologies allow for the study of differences in brain activity in people diagnosed with schizophrenia. The image shows two levels of the brain, with areas that were more active in healthy controls than in schizophrenia patients shown in orange, during an fMRI study of working memory. Credit: Kim J, Matthews NL, Park S./PLoS One.

A new study by Virginia Commonwealth University researchers suggests that dysregulation in the way two G protein-coupled receptors talk to each other may be responsible for some symptoms of schizophrenia and could lead to new treatment targets.

The study "Allosteric through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia," was published in the journal Science Signaling in January.

GPCRs are proteins that sense signaling molecules such as hormones and neurotransmitters and are the targets of many prescribed drugs. Healthy brain function relies on GPCR signaling, and alterations in this process can result in various diseases and ailments, including hypertension, diabetes and pain, as well as neurological and psychiatric disorders.

In this case, researchers analyzed the structure of two GPCRs involved in schizophrenia and antipsychotic drug action: serotonin 5-HT2A and glutamate mGlu2.

Until relatively recently, these GPCRs were assumed to function as monomeric signaling units. Monomers are proteins made up of a single polypeptide chain. In a 2008 study published in Nature by the same team, researchers discovered that these two GPCRs were actually assembled as heteromeric complexes, which contain two or more polypeptide chains, and are located in close molecular proximity at the cell surface. This structure functions in a different way than the monomeric complex and changes the way therapeutic drugs affect it, too. Building on that knowledge, researchers in the new study were able to characterize the mechanism for how 5-HT2A and mGlu2 crosstalk within the receptor complex and show that this crosstalk is altered in both lab mice and postmortem brain tissue samples of .

"We found that if you activate only the mGlu2 receptor in single cells expressing both mGlu2 and 5-HT2A, you have both Gi signaling and Gq signaling," said Javier González-Maeso, Ph.D., associate professor in the Department of Physiology and Biophysics at the VCU School of Medicine. However, when you activate the mGlu2 receptor in animals without the serotonin 5-HT2A receptor, Gq signaling doesn't occur. The brain tissue samples of schizophrenic patients indicated the same thing: Gi signaling but no Gq signaling.

Gi and Gq are molecules that control how each cell decodes the various signals coming from the GPCRs. Previous studies have shown that a specific ratio of Gi versus Gq signaling is necessary to induce antipsychotic responses in mouse models of schizophrenia.

"Our findings suggest that this crosstalk is changed in patients with schizophrenia and might be responsible for some of the symptoms," González-Maeso said.

Knowing this, researchers can consider new therapies for schizophrenia. Current treatment addresses symptoms through drugs that target one receptor. Often, these drugs either do not work or patients have severe secondary effects. About 74 percent of patients end treatment, according to González-Maeso.

"With these new findings, we set the stage for new pharmacological approaches that will allow us to balance Gi and Gq signaling with the final goal of developing new therapeutic strategies for schizophrenia treatment," González-Maeso said.

Schizophrenia is a mental illness that affects 1 percent of the U.S. population. The disease interferes with cognitive function, managing emotions and social interactions. Risk factors for include genetics, environment and brain chemistry.

Explore further: Researchers identify new drug target for schizophrenia

More information: J. L. Moreno et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia, Science Signaling (2016). DOI: 10.1126/scisignal.aab0467

Related Stories

Researchers identify new drug target for schizophrenia

August 13, 2012
(Medical Xpress) -- Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave ...

Group Therapy: New approach to psychosis treatment could target multiple nervous system receptors

February 1, 2013
Antipsychotic drugs, used in the treatment of psychotic disorders involving severe delusions and hallucinations, have been studied for more than 70 years. Currently available antipsychotic drugs, however, only alleviate certain ...

Scientists create 'fingerprints' for major drug development targets

December 2, 2015
For the first time, scientists from the Florida campus of The Scripps Research Institute (TSRI) have created detailed "fingerprints" of a class of surface receptors that have proven highly useful for drug development.

Researchers develop method for advancing development of antipsychotic drugs

November 23, 2011
Researchers interested in the treatment of schizophrenia and dementia have clarified how antipsychotic drugs that target a complex of two receptors at the surface of cells in the brain work, according to a new study published ...

New schizophrenia treatments may be effective for subgroup of patients

December 8, 2015
Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published ...

Scientists show how drug molecules regulate a medically important protein

December 10, 2015
A new study, led by scientists at The Scripps Research Institute (TSRI), shows how different pharmaceutical drugs hit either the "on" or "off" switch of a signaling protein linked to asthma, obesity and type 2 diabetes.

Recommended for you

Researchers link epigenetic aging to bipolar disorder

December 12, 2017
Bipolar disorder may involve accelerated epigenetic aging, which could explain why persons with the disorder are more likely to have - and die from - age-related diseases, according to researchers from The University of Texas ...

Researchers find common psychological traits in group of Italians aged 90 to 101

December 12, 2017
In remote Italian villages nestled between the Mediterranean Sea and mountains lives a group of several hundred citizens over the age of 90. Researchers at the University of Rome La Sapienza and University of California San ...

Twitter can reveal our shared mood

December 11, 2017
In the largest study of its kind, researchers from the University of Bristol have analysed mood indicators in text from 800 million anonymous messages posted on Twitter. These tweets were found to reflect strong patterns ...

New therapy can help schizophrenia sufferers re-engage socially

December 11, 2017
A new therapy aimed at helping young people suffering from schizophrenia to reconnect and engage with the world around them has had promising results, according to a new University of Sussex-led study.

Infant brain responses predict reading speed in secondary school

December 11, 2017
A study conducted at the Department of Psychology at the University of Jyväskylä, Finland and Jyväskylä Centre for Interdisciplinary Brain Research (CIBR) has found that the brain responses of infants with an inherited ...

Certain books can increase infant learning during shared reading, study shows

December 11, 2017
Parents and pediatricians know that reading to infants is a good thing, but new research shows reading books that clearly name and label people and objects is even better.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.